|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005821,
umls-concept:C0008976,
umls-concept:C0009566,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0034656,
umls-concept:C0035173,
umls-concept:C0220825,
umls-concept:C0245726,
umls-concept:C0332206,
umls-concept:C0441471,
umls-concept:C0443252,
umls-concept:C0475224,
umls-concept:C0522523,
umls-concept:C1257890,
umls-concept:C1273342,
umls-concept:C1522318,
umls-concept:C1522564,
umls-concept:C1545588,
umls-concept:C1708528,
umls-concept:C1879313,
umls-concept:C1948041
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-8-21
|
|
pubmed:abstractText |
Abciximab, a monoclonal antibody fragment against the platelet receptor alphaIIb beta3 integrin, prevents platelet aggregation. A randomized, placebo-controlled study showed that abciximab improves outcomes for patients undergoing percutaneous coronary angioplasty at 30 days and at 6 months.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin beta3,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Glycoprotein GPIIb-IIIa...,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vitronectin,
http://linkedlifedata.com/resource/pubmed/chemical/abciximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0098-7484
|
|
pubmed:author |
pubmed-author:AndersonK MKM,
pubmed-author:CaliffR MRM,
pubmed-author:EllisS GSG,
pubmed-author:FergusonJ JJJ,
pubmed-author:IvanhoeR JRJ,
pubmed-author:KleimanN SNS,
pubmed-author:MillerD PDP,
pubmed-author:TchengJ EJE,
pubmed-author:TopolE JEJ,
pubmed-author:WangA LAL,
pubmed-author:WeismanH FHF
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
13
|
|
pubmed:volume |
278
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
479-84
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9256222-Angioplasty, Balloon, Coronary,
pubmed-meshheading:9256222-Antibodies, Monoclonal,
pubmed-meshheading:9256222-Antigens, CD,
pubmed-meshheading:9256222-Coronary Disease,
pubmed-meshheading:9256222-Double-Blind Method,
pubmed-meshheading:9256222-Drug Administration Schedule,
pubmed-meshheading:9256222-Female,
pubmed-meshheading:9256222-Follow-Up Studies,
pubmed-meshheading:9256222-Humans,
pubmed-meshheading:9256222-Immunoglobulin Fab Fragments,
pubmed-meshheading:9256222-Infusions, Intravenous,
pubmed-meshheading:9256222-Injections, Intravenous,
pubmed-meshheading:9256222-Integrin beta3,
pubmed-meshheading:9256222-Male,
pubmed-meshheading:9256222-Middle Aged,
pubmed-meshheading:9256222-Multivariate Analysis,
pubmed-meshheading:9256222-Myocardial Ischemia,
pubmed-meshheading:9256222-Myocardial Revascularization,
pubmed-meshheading:9256222-Platelet Aggregation Inhibitors,
pubmed-meshheading:9256222-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:9256222-Platelet Membrane Glycoproteins,
pubmed-meshheading:9256222-Proportional Hazards Models,
pubmed-meshheading:9256222-Receptors, Vitronectin,
pubmed-meshheading:9256222-Survival Analysis
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
|
|
pubmed:affiliation |
Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA. topole@cesmtp.ccf.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
